A study of the effects of drugs used to treat epilepsy on semen, sex hormones and sexual function in young male patients with epilepsy

Submission date	Recruitment status	Prospectively registered
12/04/2020	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
26/04/2020	Completed	Results
Last Edited	Condition category Nervous System Diseases	Individual participant data
24/04/2020		Record updated in last year

Plain English summary of protocol

Background and study aims

Epilepsy is a common condition that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affect how it works. Epilepsy is a common chronic neurological disorder with a worldwide prevalence of approximately 1%. Globally, there were 45.9 million patients with active epilepsy (both idiopathic and secondary epilepsy) in 2016. The first-line therapy for epilepsy is antiepileptic drugs (AEDs) treatment, and approximately 70% of people with epilepsy can achieve seizure control with a single antiepileptic medication. The National Institute for Health and Care Excellence guidelines recommend carbamazepine (CBZ) or lamotrigine (LTG) as first-line treatment options for patients with newly diagnosed partial seizures and then recommend levetiracetam (LEV), OXC, or VPA if CBZ and LTG are unsuitable or not tolerated. High-quality evidence also indicates that CBZ and LTG are suitable first-line treatments for patients with partial-onset seizures and demonstrates that LEV may be a suitable alternative. However, because CBZ and LTG have higher rash rates than the other three drugs, LEV is more expensive than OXC or VPA. Therefore, VPA and OXC continue to be commonly used AEDs for partial seizures. Clinical studies on the side effects of VPA and OXC have mostly focused on liver and gastrointestinal dysfunction, abnormal blood parameters, rashes and similar effects. It has been reported that VPA and OXC may be associated with decreased sexual function and increased frequency of morphologically abnormal sperm. There is evidence that VPA can lead to a significant reduction in the levels of FSH and testosterone (T) in male patients with epilepsy compared with healthy controls.

However, there remains controversy regarding the effects of VPA and OXC on the sexual function of male patients with epilepsy. Moreover, there have been few studies regarding the effects of OXC on semen quality and sex hormone levels. At the same time, due to the demand for reproductive health in reproductive-aged men, the current study aimed to evaluate the effects of VPA and OXC on sexual function, semen, and sex hormones in newly diagnosed young male epilepsy patients and provide a reference for AED selection in these patients.

Who can participate?

Adult male patients with simple partial seizures, complex partial seizures or secondarily generalized seizures. Healthy young male volunteers form the control group.

What does the study involve?

Participants will have semen quality, sex hormone levels, and sexual function assessments at baseline and six months. Epilepsy patients will be randomly allocated to receive one of two different epilepsy drugs for the six month study period.

What are the possible benefits and risks of participating? None.

Where is the study run from? Epilepsy Center of People's Hospital of Sichuan Province (China)

When is the study starting and how long is it expected to run for? September 2014 to December 2016

Who is funding the study? Sichuan Provincial People's Hospital for Doctors or Youths (China)

Who is the main contact? Qiong' Zhu, zhuqiong427@126.com

Contact information

Type(s)

Scientific

Contact name

Mr Qiong' Zhu

ORCID ID

http://orcid.org/0000-0001-7747-8975

Contact details

Sichuan Provincial People's Hospital 32# W. Sec 2
1st Ring Rd.
Chengdu
China
610000
+86 17708130527
zhuqiong427@126.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

The effects of sodium valproate and oxcarbazepine on semen, sex hormones and sexual function in young male patients with epilepsy

Study objectives

This study aims to evaluate the effect of VPA and OXC on semen quality, sex hormones and sexual function in young male patients with partial epilepsy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/03/2013, Ethics committee of Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital (32# W. Sec 2, 1st Ring Rd. Chengdu, China; +86-028-87393265; no email provided), ref: none provided

Study design

Observational case-control

Primary study design

Observational

Secondary study design

Case-control study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Epilepsy

Interventions

Semen quality and sex hormone levels are assessed in newly diagnosed young male epileptic patients and healthy volunteers who meet the inclusion criteria. Additionally, a sexual function questionnaire survey will be conducted using the International Index of Erectile Function 5 (IIEF-5) regarding participants' sexual life. Semen quality, sexual function questionnaire scores and sex hormone results will be compared between the two groups.

The epileptic patients are treated with VPA (trade name: Depakote; packing specification: 500 mg × 30 pieces; Manufacturing: Sailof (Hangzhou) Pharmaceutical Co., Ltd.; batch number: H2O010595) or OXC (trade name: Trileptal; packing specification: 0.3 g × 50 pieces; Manufacturing: Novartis Farma S.P.A. (Italy); batch number: H2O130016) randomly.

The dosage of VPA is initially 250 mg twice daily, then gradually increased to an effective dose, and the maximum daily dose will not exceed 30 mg/kg. The dosage of OXC is initially 300 mg twice daily, then gradually increased to an effective dose, and the maximum daily dose will not exceed 2400 mg/d. All patients will be followed up once a month by a doctor. After 6 months of treatment, the semen quality and sex hormones of the patients will be tested again, and the IIEF-5 questionnaire used to evaluate the patients' sexual life. Semen quality, sexual function questionnaire scores, and sex hormone levels will be compared between the VPA group and the OXC group before and after treatment.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Sodium valproate, oxcarbazepine

Primary outcome measure

Quality of semen measured using lab test of semen sample at baseline and six months

Secondary outcome measures

- 1. Sex hormones measured using lab test of blood sample at baseline and six months
- 2. Sexual function measured using International Index of Erectile Function 5 (IIEF-5) at baseline and six months

Overall study start date

13/01/2013

Completion date

15/12/2016

Eligibility

Key inclusion criteria

- 1. Patients with simple partial seizures, complex partial seizures or secondarily generalized seizures
- 2. Healthy young male volunteers (control group)

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

77

Key exclusion criteria

- 1. Use of hormones, antidepressants, or drugs to improve sexual function
- 2. Liver and kidney dysfunction, thyroid disease, diabetes, infectious diseases, varicocele, cryptorchidism, history of testicular surgery, Klinefelter syndrome, or urinary system diseases
- 3. Long-term alcoholism, smoking, or exposure to toxic substances
- 4. Mental illness, intracranial occupying lesions, brain injury, or progressive degeneration of the nervous system
- 5. Inability to cooperate or refusal to participate in the study

Individual participation in the study was terminated if any of the following conditions were met:

- 1. Patients experienced adverse drug reactions after taking the medications and needed to discontinue the drug
- 2. Patients failed to achieve an ideal treatment effect (i.e., the reduction in the frequency of epileptic seizures is less than 75% after three months of treatment), and other AEDs needed to be substituted or added
- 3. Patients or volunteers took medications or suffered from diseases that might affect the results during the study
- 4. Participants withdrew from the study for personal reasons

Date of first enrolment

30/09/2014

Date of final enrolment

01/12/2016

Locations

Countries of recruitment

China

Study participating centre Epilepsy Center of People's Hospital of Sichuan Province

32# W. Sec 2, 1st Ring Rd. Chengdu

China

610000

Sponsor information

Organisation

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Sponsor details

32# W. Sec 2 1st Ring Rd. Chengdu China 610000 +86-028-87393265 zhuqiong427@126.com

Sponsor type

University/education

Website

https://www.samsph.com/

ROR

https://ror.org/01qh26a66

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Sichuan Provincial People's Hospital for Doctors or Youths

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

30/12/2025

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication.

IPD sharing plan summary Other